{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:47:17Z","timestamp":1776235637695,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.nbd.2025.106801","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T16:34:54Z","timestamp":1736613294000},"page":"106801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["14-3-3\u03b8 phosphorylation exacerbates alpha-synuclein aggregation and toxicity"],"prefix":"10.1016","volume":"206","author":[{"given":"Bing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Gannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudradip","family":"Pattanayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasandra","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank Sanders","family":"Pair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roschongporn","family":"Ekkatine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talene A.","family":"Yacoubian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2025.106801_bb0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.chembiol.2023.04.005","article-title":"IFN\u03b1 primes cancer cells for Fusicoccin-induced cell death via 14-3-3 PPI stabilization","volume":"30","author":"Andlovic","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.nbd.2025.106801_bb0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ana.10621","article-title":"Specification of 14-3-3 proteins in Lewy bodies","volume":"54","author":"Berg","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2025.106801_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020375","article-title":"Alpha-synuclein: mechanisms of release and pathology progression in synucleinopathies","volume":"10","author":"Br\u00e1s","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.nbd.2025.106801_bb0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ibneur.2022.11.007","article-title":"The BE (2)-M17 cell line has a better dopaminergic phenotype than the traditionally used for Parkinson\u2019s research SH-SY5Y, which is mostly serotonergic","volume":"13","author":"Carvajal-Oliveros","year":"2022","journal-title":"IBRO Neurosci. Rep."},{"key":"10.1016\/j.nbd.2025.106801_bb0025","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1111\/febs.15674","article-title":"Molecular events underlying the cell-to-cell transmission of \u03b1-synuclein","volume":"288","author":"Choi","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.nbd.2025.106801_bb0030","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1111\/j.1742-4658.2005.04765.x","article-title":"BCR kinase phosphorylates 14-3-3 tau on residue 233","volume":"272","author":"Clokie","year":"2005","journal-title":"FEBS J."},{"key":"10.1016\/j.nbd.2025.106801_bb0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1096\/fj.10-164624","article-title":"Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity","volume":"25","author":"Danzer","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.nbd.2025.106801_bb0040","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/archneur.65.8.1074","article-title":"Incidental Lewy body disease and preclinical Parkinson disease","volume":"65","author":"DelleDonne","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.nbd.2025.106801_bb0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00401-008-0345-7","article-title":"Evidence that incidental Lewy body disease is pre-symptomatic Parkinson\u2019s disease","volume":"115","author":"Dickson","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2025.106801_bb0050","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/mds.25952","article-title":"Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson\u2019s disease","volume":"29","author":"Dijkstra","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2025.106801_bb0055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41531-021-00230-6","article-title":"Pathways to Parkinson's disease: a spotlight on 14-3-3 proteins","volume":"7","author":"Giusto","year":"2021","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.nbd.2025.106801_bb0060","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1523\/JNEUROSCI.22-15-06309.2002","article-title":"Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage","volume":"22","author":"Gorski","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2025.106801_bb0065","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1212\/WNL.0000000000002102","article-title":"Parkinson disease and incidental Lewy body disease: just a question of time?","volume":"85","author":"Iacono","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2025.106801_bb0070","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.neuron.2017.02.018","article-title":"Small-molecule stabilization of 14-3-3 protein-protein interactions stimulates axon regeneration","volume":"93","author":"Kaplan","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2025.106801_bb0075","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.chembiol.2020.02.010","article-title":"Polypharmacological perturbation of the 14-3-3 adaptor protein interactome stimulates neurite outgrowth","volume":"27","author":"Kaplan","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.nbd.2025.106801_bb0080","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jnen\/61.3.245","article-title":"14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains","volume":"61","author":"Kawamoto","year":"2002","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2025.106801_bb0085","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/acscentsci.2c01449","article-title":"A systematic approach to the discovery of protein-protein interaction stabilizers","volume":"9","author":"Kenanova","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.nbd.2025.106801_bb0090","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1515\/hsz-2019-0405","article-title":"Small-molecule modulation of p53 protein-protein interactions","volume":"401","author":"Kuusk","year":"2020","journal-title":"Biol. Chem."},{"key":"10.1016\/j.nbd.2025.106801_bb0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00401-024-02781-3","article-title":"Current insights and assumptions on \u03b1-synuclein in Lewy body disease","volume":"148","author":"Leak","year":"2024","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2025.106801_bb0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1042\/BJ20031332","article-title":"Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes","volume":"381","author":"Mackintosh","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.nbd.2025.106801_bb0105","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/acn3.421","article-title":"Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology","volume":"4","author":"McFerrin","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.nbd.2025.106801_bb0110","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1515\/BC.2006.152","article-title":"14-3-3 proteins in membrane protein transport","volume":"387","author":"Mrowiec","year":"2006","journal-title":"Biol. Chem."},{"key":"10.1016\/j.nbd.2025.106801_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167930","article-title":"The hidden cell-to-cell trail of \u03b1-synuclein aggregates","volume":"435","author":"Neupane","year":"2023","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2025.106801_bb0120","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tips.2021.01.001","article-title":"14-3-3 proteins: novel pharmacological targets in neurodegenerative diseases","volume":"42","author":"Pair","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.nbd.2025.106801_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddae142","article-title":"14-3-3 phosphorylation inhibits 14-3-3\u03b8\u2019s ability to regulate LRRK2 kinase activity and toxicity","author":"Pattanayak","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2025.106801_bb0130","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1093\/hmg\/ddu275","article-title":"The chaperone-like protein 14-3-3eta interacts with human alpha-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing alpha-synuclein cellular toxicity","volume":"23","author":"Plotegher","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2025.106801_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167406","article-title":"Recent advances in genetic code expansion techniques for protein phosphorylation studies","volume":"434","author":"Qin","year":"2022","journal-title":"J. Mol. Biol."},{"issue":"Suppl. 1","key":"10.1016\/j.nbd.2025.106801_bb0140","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1186\/1477-5956-9-S1-S6","article-title":"Prediction of 492 human protein kinase substrate specificities","volume":"9","author":"Safaei","year":"2011","journal-title":"Proteome Sci."},{"key":"10.1016\/j.nbd.2025.106801_bb0145","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.nbd.2025.106801_bb0150","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.molcel.2023.02.018","article-title":"A central chaperone-like role for 14-3-3 proteins in human cells","volume":"83","author":"Segal","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.nbd.2025.106801_bb0155","doi-asserted-by":"crossref","first-page":"13759","DOI":"10.1073\/pnas.0606179103","article-title":"A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression","volume":"103","author":"Shin","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.nbd.2025.106801_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021720","article-title":"14-3-3theta protects against neurotoxicity in a cellular Parkinson\u2019s disease model through inhibition of the apoptotic factor Bax","volume":"6","author":"Slone","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nbd.2025.106801_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2015.02.032","article-title":"Increased 14-3-3 phosphorylation observed in Parkinson\u2019s disease reduces neuroprotective potential of 14-3-3 proteins","volume":"79","author":"Slone","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2025.106801_bb0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.abb.2014.03.008","article-title":"Chaperone-like activity of monomeric human 14-3-3zeta on different protein substrates","volume":"549","author":"Sluchanko","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.nbd.2025.106801_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2022.102169","article-title":"Molecular glues to stabilise protein-protein interactions","volume":"69","author":"Soini","year":"2022","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.nbd.2025.106801_bb0180","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2025.106801_bb0185","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.molmed.2020.03.012","article-title":"Cell-to-cell transmission of tau and \u03b1-synuclein","volume":"26","author":"Uemura","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.nbd.2025.106801_bb0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40478-020-01110-5","article-title":"14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model","volume":"9","author":"Underwood","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2025.106801_bb0195","doi-asserted-by":"crossref","first-page":"20029","DOI":"10.1074\/jbc.271.33.20029","article-title":"14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules","volume":"271","author":"Vincenz","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2025.106801_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106166","article-title":"Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-a decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models","volume":"183","author":"Vinueza-Gavilanes","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2025.106801_bb0205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2025.106801_bb0210","article-title":"14-3-3Tau regulates Beclin 1 and is required for autophagy","volume":"5","author":"Wang","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nbd.2025.106801_bb0215","doi-asserted-by":"crossref","first-page":"8211","DOI":"10.1523\/JNEUROSCI.1134-18.2018","article-title":"14-3-3 proteins reduce cell-to-cell transfer and propagation of pathogenic alpha-synuclein","volume":"38","author":"Wang","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2025.106801_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2024.1470171","article-title":"Intercellular transmission of alpha-synuclein","volume":"17","author":"Wu","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.nbd.2025.106801_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2009.4","article-title":"Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson\u2019s disease","volume":"1","author":"Yacoubian","year":"2010","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.nbd.2025.106801_bb0230","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1091\/mbc.e06-03-0229","article-title":"A novel function of 14-3-3 protein: 14-3-3zeta is a heat-shock-related molecular chaperone that dissolves thermal-aggregated proteins","volume":"17","author":"Yano","year":"2006","journal-title":"Mol. Biol. Cell"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996125000178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996125000178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:44:08Z","timestamp":1740462248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996125000178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":46,"alternative-id":["S0969996125000178"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2025.106801","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"14-3-3\u03b8 phosphorylation exacerbates alpha-synuclein aggregation and toxicity","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2025.106801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106801"}}